Amgen Inc. v. Sanofi

  1. September 02, 2021

    The Latest Fed. Circ. Antibody Rulings You Need To Know

    Since the beginning of 2021, the Federal Circuit has invalidated several antibody patents in cases that have deeply split the pharmaceutical industry and taken down a billion-dollar verdict. Here is a look at how the judges are handling these infringement and invalidity fights.

  2. July 07, 2021

    5 Patent Cases To Watch In The Second Half Of 2021

    The U.S. Supreme Court will be deciding later this year whether to take up a highly controversial patent eligibility case, while a California federal court mulls whether discretionary denial precedent at the Patent Trial and Appeal Board is legal. Here are five cases in patent attorneys' sights for the rest of the year.

  3. June 21, 2021

    Fed. Circ. Won't Eye Amgen Case But Disputes 'Sky Is Falling'

    The full Federal Circuit on Monday refused to revisit a decision that invalidated two of Amgen's patents on its cholesterol medication Repatha, though a panel of judges disputed the drugmaker's "sky is falling" approach in arguing that the ruling changed the law.

  4. June 01, 2021

    Sanofi Rips Fed. Circ. Rehearing Bid In Repatha IP Fight

    Sanofi is defending a controversial Federal Circuit ruling that axed two Amgen patents covering the cholesterol medication Repatha, arguing that Amgen's claims that the full court should review the ruling because it created too strict of an enablement test for patents in the biologics industry show that its rival is "swinging for the fences."

  5. April 28, 2021

    GSK Says Amgen Patent Decision Will 'Devastate' Innovation

    Pharmaceutical giant GlaxoSmithKline PLC on Wednesday threw its support behind Amgen in a patent dispute over the cholesterol medication Repatha, telling the Federal Circuit that a panel's decision earlier this year finding that the patents covering the drug are too broad to be enabled threatens to "devastate" innovation.

  6. April 15, 2021

    Amgen Tells Full Fed. Circ. Antibody IP Ax Dooms Biologics

    Amgen has asked the full Federal Circuit to review a panel's determination that two patents covering its cholesterol medication Repatha are too broad to be enabled, a decision it said created too strict of an enablement test that stands to stymie "breakthrough inventions."

  7. February 18, 2021

    Biologics Face Tougher Patent Scrutiny After Amgen Ruling

    A recent Federal Circuit decision clamping down on broad antibody patent claims may have some biologics makers scrambling to save their existing intellectual property and questioning whether to patent future drugs at all.

  8. February 11, 2021

    Fed. Circ. Says Amgen's Repatha Patents Are Too Expansive

    A Delaware federal judge rightly found that claims of two Amgen patents covering its cholesterol medication Repatha are too broad to be enabled, the Federal Circuit said Thursday in a win for Sanofi and Regeneron.

  9. December 09, 2020

    Fed. Circ. Judge Skeptical Amgen Cholesterol Drug IP Is Valid

    A Federal Circuit judge told an attorney Wednesday he faced an "uphill battle" in showing two Amgen patents on cholesterol-lowering drug Repatha are valid, casting doubt on the biopharmaceutical giant's closely watched bid to undo a district court win for its rival Sanofi.

  10. August 21, 2020

    Pharma Giants Tee Up Biologics Innovation Fight At Fed. Circ.

    In the middle of a pandemic where antibodies are at the center of prevention and treatment research, the Federal Circuit is weighing a case that could deeply impact how drugmakers can patent biologics, an issue that is not only critical to coronavirus research but to pharma at large.